🚀 Calling all aspiring scientists from low- and middle-income countries! 🔬 The Next Generation Scientist Program, run by Novartis and the University of Basel, is a 3-month, fully-funded internship in Basel, Switzerland. From June 1 - August 31, 2025, interns will work on cutting-edge research, gain leadership skills, and learn about drug discovery and development—guided by expert mentors. 🌍 The program is designed to build scientific and leadership capabilities in low- and middle-income countries, empowering participants to bring their new skills and knowledge back to their communities and maximize our collective impact on society. 📅 Interested in addressing global health challenges like malaria or sickle cell disease? Apply by October 31: https://lnkd.in/d54H_Qp4 🎥 Get inspired and hear from this year's interns in the video below. Novartis | University of Basel | #NextGenerationScientist | #GlobalHealth | #Opportunity
Novartis Global Health
Arzneimittelherstellung
Basel, Basel-Town 33.759 Follower:innen
We address health challenges and inequities where we can make a unique contribution and overcome barriers to healthcare.
Info
In Novartis Global Health, we have a shared ambition to ensure everyone can benefit from our innovation regardless of where they live or their socio-economic situation; and to maximize our social impact as a sustainable business. We bring a combination of global health and business capabilities to do so, and address select health challenges and inequities where we can make a unique contribution. Together with our partners, we expand access to treatment for as many people as possible. See our community guidelines: https://bit.ly/35ExptC.
- Website
-
https://bit.ly/novartisglobalhealth
Externer Link zu Novartis Global Health
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Basel, Basel-Town
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1996
- Spezialgebiete
- Malaria, Sickle cell disease, Leprosy, Chagas disease, Cardiovascular disease, Cancer, Neuroscience und Ophthalmology
Orte
-
Primär
Novartis Campus
Basel, Basel-Town 4056, CH
Beschäftigte von Novartis Global Health
-
Taufiq Jiwani (TJ), Ed.D
Coaching Leaders | Trainer-Facilitator-SME | Executive Account Specialist | Sales Leadership | Community Service
-
Michael Robinson
Director Global Program and Partnership Management at Novartis Institutes for BioMedical Research (NIBR)
-
Brenda Law-Whitfield
District Activist Leader (DAL) - 9th Congressional District - TX at National MS Society
-
Jason T. Shellaby
Director, External Affairs & Strategic Partnerships, Novartis Global Health
Updates
-
Novartis Global Health hat dies direkt geteilt
Climate change has an undeniable impact on human health, and future doctors will witness that impact at scale. Equipping healthcare professionals with knowledge about this interface is crucial to address these challenges effectively. I’m pleased to share that Novartis is supporting the launch of the European Network on Climate & Health Education (ENCHE), a network of 25 top European universities that will equip 10,000 next-generation healthcare professionals with the knowledge and skills to address the health impacts of climate change and deliver sustainable healthcare. Complementary to our ambitious efforts in mitigating our own impact on the environment, this network is a promising example of how preserving and sharing today’s knowledge and skills will enable future generations to adapt to tomorrow's challenges. Learn more about the European Network on Climate and Health here: https://lnkd.in/ddjqWN4Q Novartis | Novartis Global Health | Sustainable Markets Initiative | #ClimateHealth
-
💬 "We have a real opportunity to solve tomorrow’s challenges with the innovative tools and collaborations we are building today." Lutz Hegemann, President of Global Health & Sustainability, shares his reflections on the 79th United Nations General Assembly in his latest article. Read it here: https://lnkd.in/esjMpWNX
We have a real opportunity to solve tomorrow’s challenges with the innovative tools and collaborations we are building today. The 79th United Nations General Assembly (UNGA) reaffirmed this truth. However, to truly meet the diverse health needs of society, we must focus on health inclusion. In this article, I reflect on three significant events at UNGA which emphasized the need for equitable innovation and collaboration to create impact. I welcome your thoughts in the comments. A big thank you to Clinton Global Initiative, Foreign Policy, UN Climate Change, Climate Action, EY, and all our partners for the rich conversations. #UNGA79 | #CGI24 | Novartis | Novartis Global Health | Novartis Foundation | Ann Aerts | Binta Beard | Carrie Scott | Lucy Gugen
The need for equitable innovation and collaboration to create impact: Reflections from the 79th UNGA
Lutz Hegemann auf LinkedIn
-
At Novartis, we believe that eliminating #leprosy can be done. In the next step of our commitment towards elimination of the disease, we have launched together with partners, the Morogoro Leprosy Elimination Program (MoLEP) in Tanzania. The program seeks to support the National Tuberculosis and Leprosy Programme (NTLP) of the Tanzania Ministry of Health in demonstrating the feasibility of interrupting leprosy transmission through: 🔎 active case finding 🤝 contact tracing 💊 post-exposure prophylaxis Through MoLEP, we hope to be able to set the standard for replication in other parts of Tanzania, and other countries that aspire to eliminate leprosy. Swiss Tropical and Public Health Institute | German Leprosy and TB Relief Association (DAHW) | World Health Organization | 𝐓𝐚𝐧𝐳𝐚𝐧𝐢𝐚 𝐌𝐢𝐧𝐢𝐬𝐭𝐫𝐲 𝐨𝐟 𝐇𝐞𝐚𝐥𝐭𝐡 | 𝐆𝐥𝐨𝐛𝐚𝐥 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐟𝐨𝐫 𝐙𝐞𝐫𝐨 𝐋𝐞𝐩𝐫𝐨𝐬𝐲
-
Did you know a parasite can cause one of the deadliest forms of heart failure? Heart failure caused by Chagas disease has higher hospitalization rates and higher mortality rates compared with other causes of heart failure, and Chagas patients report worse health-related quality of life. This is why early cardiovascular assessment for all Chagas patients is needed. #WorldHeartDay | World Heart Federation | Interamerican Society of Cardiology | Barcelona Institute for Global Health (ISGlobal) | Chagas Coalition
-
Global warming is breeding more than just extreme weather – it’s spreading deadly diseases like visceral leishmaniasis (also known as kala-azar, which translates as ‘black fever’). We are proud to partner with Drugs for Neglected Diseases initiative - DNDi on the development of a potential first-in-class treatment discovered with financial support from Wellcome Trust. With governments, NGOs, and other partners all taking action, we can #beatNTDs. Read more about the growing threat of visceral leishmaniasis in this Devex article (paywall): https://bit.ly/4cMn1ik #NTDs
What is kala-azar, and why are health experts alarmed by its rising spread?
devex.com
-
Bringing malaria clinical trials to remote areas is essential to advance science and build healthcare capacity in the communities that need it most. But we can’t do it alone – it takes dedicated partners to reach malaria patients in hard-to-access regions. One of our key partners in this mission is the European & Developing Countries Clinical Trials Partnership (EDCTP). Their significant support is helping us run clinical trials targeting the unmet needs of patients with severe malaria and those of babies under 5kg with malaria, for whom no approved treatment yet exists. As antimalarial resistance and other challenges emerge, strong partnerships like this will be ever more vital. A huge thank you to EDCTP and all our partners for their continued commitment and support. Together, we are making strides against malaria. Read more about how we are tackling the challenge of malaria clinical trials in Africa in In Vivo: https://bit.ly/3SFBAx7 Medicines for Malaria Venture | Swiss Tropical and Public Health Institute
-
Imagine transforming a shipping container into a fully equipped clinical trial site for malaria. This is what happened in Lubumbashi, Democratic Republic of the Congo, where with the support of Novartis and Medicines for Malaria Venture, the Swiss Tropical and Public Health Institute flew a ‘lab in a box’ – a fully equipped shipping container that was assembled on site. This will become a semi-permanent facility for current and future clinical trials. This solution underscores the importance of conducting clinical trials where the highest burden of disease is, even when it means investing in infrastructure and taking risks to reach remote communities. We believe that bringing clinical trials to hard-to-reach areas is important not just to advance science – but also to build lasting healthcare capacity in the communities that need it most. Read more in In Vivo: https://bit.ly/3SFBAx7 | European & Developing Countries Clinical Trials Partnership Photo credits: Christelle Laufenburger/Swiss TPH
-
Yopougon commune in Abidjan, Côte d'Ivoire, now has its first comprehensive sickle cell disease center for treating the life-threatening condition, #sicklecell disease. Novartis, in partnership with the Swiss Center of Scientific Research (Centre Suisse de Recherches Scientifiques en Côte d'Ivoire) and Swiss Tropical and Public Health Institute, will support the center in Abidjan which will provide specialized care and further research initiatives to advance treatment options. About 80% of the global sickle cell disease (#SCD) burden is in Africa, where at least 50% of children born with SCD die before their fifth birthday. Côte d'Ivoire has an estimated SCD prevalence of 2% with under-5 mortality similar to other African countries. The World Health Organization has identified early diagnosis as a key measure in the fight against the hereditary blood disorder, and the center will integrate screening and diagnosis into primary health care services. The goal is to enroll over 70% of screen-positive patients in a comprehensive disease management program and adopt technology solutions to ensure continuity of care and quality data collection. In addition, nurses and community healthcare workers will be trained on the use of SCD point-of-care devices and genetic counseling in a community-based setting. This SCD center which is located within the Yopougon Millionnaire Extension Mixed Health Center, is part of a partnership between #Yopougon community and the Swiss Kanton Basel-Stadt. The Yopougon Health Center includes general medicine, obstetrics, pediatrics and dentistry services, as well as a pharmacy and laboratory. Lutz Hegemann I Manon COULIBALY I Nicola Lister I Gesa. Pellier I Adeline Edgal I Dr Cinthia Manzan I Kwaku Marfo, PharmD., MPH, MBA I KOFFI Aka Charles I GUELADIO CISSE I Charles Abongomera
-
📜 Science has just published ground-breaking findings from Novartis scientists that point to a new, accessible therapeutic approach for people in all parts of the world who are living with #sicklecell disease (SCD). The manuscript details research into a new approach for inducing fetal hemoglobin production. Higher fetal hemoglobin levels significantly reduce morbidity and mortality in #SCD. The goal of Novartis research is an improved oral treatment that addresses the unmet need for accessible options for patients in low- and middle-income regions, where the disease burden is greatest. https://lnkd.in/dZ3CTCmj Pamela Ting I Jay Bradner